knowledge -WSS

knowledge

author：knowledge 2025-08-11 09:46:11 - browse：839

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Senate panel clears PBM, hopsital reforms

leisure time

WSS

How Brent Saunders' Allergan experiment failed

Biden White House, tech companies launch new safeguards around emerging AI technology

Diversify hospital leadership teams to protect BIPOC patient health

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Hey, doctors: Don't be no

New chief aims to remake Sanofi Genzyme

knowledge

knowledge

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

EMA weighs against approval for Mirati's lung cancer drug

How to save PrEP access — and even expand it

Medicare will require more price transparency from hospitals

Medicare details structure of new drug price negotiation program

Trump Organization, Michael Cohen agree to settle million

Walensky prepares to leave CDC — and Congress — behind

The new shift in health care is toward less care

hotspot

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Sanofi CEO defends move to abandon profit guidance, boost research

Victims of gun violence feel impacts long after bullet wound

'The View' co

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

A former Republican legislative candidate has been charged for his role in the US Capitol riot

entertainment

leisure time

hotspot

explore